Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.

@article{Leshchenko2014IntegrativeGA,
  title={Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.},
  author={Violetta V. Leshchenko and Pei-Yu Kuo and Zewei Jiang and Venu K. Thirukonda and Samir M Parekh},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 2},
  pages={382-92}
}
PURPOSE Despite advances, there is an urgent need for effective therapeutics for relapsed diffuse large B-cell lymphoma, particularly in elderly patients and primary central nervous system (CNS) lymphoma. Temozolomide (TMZ), an oral DNA-alkylating agent routinely used in the therapy of glioblastoma multiforme, is active in patients with primary CNS lymphoma but the response rates are low. The mechanisms contributing to TMZ resistance are unknown. EXPERIMENTAL DESIGN We undertook an unbiased… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…